Sonnet BioTherapeutics Holdings Inc. filings document the regulatory record of a clinical-stage oncology biotechnology company built around the FHAB biologic-drug platform. Its disclosures cover shareholder votes, board elections, executive compensation matters, auditor ratification and other proxy governance subjects.
Material-event filings also describe capital-structure activity, including convertible notes, warrants, private-placement proceeds and Nasdaq continued-listing compliance. Additional 8-K disclosures record employment and compensation arrangements, stockholder meeting results, material agreements, operating and financial results, and risk-related matters tied to the company’s biotechnology business and public-company status.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
86.46%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
How many Sonnet BioTherapeutics Holdings (SONN) SEC filings are available on StockTitan?
StockTitan tracks 43 SEC filings for Sonnet BioTherapeutics Holdings (SONN), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Sonnet BioTherapeutics Holdings (SONN)?
The most recent SEC filing for Sonnet BioTherapeutics Holdings (SONN) was filed on July 25, 2025.